Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Auditory Function with Co-artemether in Malaria
NCT00386750Phase 4Terminated
- Sponsor
- Novartis
- Start
- Jun 2005
- Primary completion
- Nov 2005
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, open-label trial of artemether + lumefantrine in Plasmodium falciparum malaria, sponsored by Novartis. Primary endpoint: Auditory abnormalities assessed by Auditory Brainstem Response (ABR) wave form latencies at Day 7. Started Jun 2005; status: terminated.
02
Drugs
artemether + lumefantrine
03
Conditions
Plasmodium falciparum malaria
Beyond the preview
Go deeper on NCT00386750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00386750.